ArticlePloS one2026
Exploration of acetylation-related biomarkers in osteoarthritis through bioinformatics analysis.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is characterized as a chronic degenerative disorder affecting the joints. A growing body of evidence indicates that acetylation may play a role in the disease's pathogenesis. However, the underlying molecular mechanisms remain largely undefined. The objective of this study was to explore potential biomarkers linked to acetylation in OA through a comprehensive bioinformatics analysis. We utilized datasets GSE55235, GSE55457, and GSE12021 from the Gene Expression Omnibus (GEO) to identify differentially expressed genes (DEGs) by employing the limma package, followed by functional enrichment analyses. By implementing weighted gene co‑expression network analysis (WGCNA), we identified key modules and subsequently recognized acetylation-related differentially expressed genes (ACEDEGs). A protein-protein interaction (PPI) network was constructed for these ACEDEGs, and machine learning algorithms were applied to discover potential biomarkers. We established and validated a diagnostic prediction model demonstrating significant diagnostic efficacy (AUC: 0.983 for training and 0.743 for validation). Furthermore, analyses indicated notable alterations in immune cell infiltration through CIBERSORT. Additionally, qRT-PCR and Western blotting corroborated the down-regulation of biomarkers JUN and MYC in OA. In summary, JUN and MYC were identified as novel acetylation-related biomarkers in OA. These findings offer valuable insights into the disease's pathophysiology and suggest new pathways for diagnostic and therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.